antihemophilic factor human

Antihemophilic factor human is a plasma-derived protein product containing concentrated coagulation Factor VIII. It is used as a replacement therapy to treat and prevent bleeding episodes in patients with hemophilia A (congenital Factor VIII deficiency). The drug works by temporarily raising plasma levels of Factor VIII to enable normal blood clotting. Mechanistically, it acts as a co-factor for activated Factor IX to activate Factor X in the intrinsic pathway of the coagulation cascade. This leads to the conversion of prothrombin to thrombin and ultimately facilitates clot formation. Antihemophilic factor human is not indicated for use in patients with von Willebrand disease[1][2][4][8]. The product was developed by companies such as CSL Behring and Baxter Healthcare[2].

Brand names

HemofilKoateWilateHemofil-MKoate-DVIMonoclate-P

Other names

antihemophilic factor humancoagulation factor VIII (human)factor VIII concentrate (human)anti-hemophilic factor (AHF)